183 related articles for article (PubMed ID: 32228210)
1. Use of liposomal nanoformulations in antileishmania therapy: challenges and perspectives.
Téllez J; Echeverry MC; Romero I; Guatibonza A; Santos Ramos G; Borges De Oliveira AC; Frézard F; Demicheli C
J Liposome Res; 2021 Jun; 31(2):169-176. PubMed ID: 32228210
[TBL] [Abstract][Full Text] [Related]
2. Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Ortega V; Giorgio S; de Paula E
J Liposome Res; 2017 Sep; 27(3):234-248. PubMed ID: 28874072
[TBL] [Abstract][Full Text] [Related]
3. Application of nanotechnology in treatment of leishmaniasis: A Review.
Akbari M; Oryan A; Hatam G
Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
[TBL] [Abstract][Full Text] [Related]
4. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.
Jamshaid H; Din FU; Khan GM
J Nanobiotechnology; 2021 Apr; 19(1):106. PubMed ID: 33858436
[TBL] [Abstract][Full Text] [Related]
6. Liposomal drug delivery systems for the treatment of leishmaniasis.
Tuon FF; Dantas LR; de Souza RM; Ribeiro VST; Amato VS
Parasitol Res; 2022 Nov; 121(11):3073-3082. PubMed ID: 36112211
[TBL] [Abstract][Full Text] [Related]
7. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
8. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
[TBL] [Abstract][Full Text] [Related]
9. Revolutionizing Leishmaniasis Treatment with Cutting Edge Drug Delivery Systems and Nanovaccines: An Updated Review.
Tambe S; Nag S; Pandya SR; Kumar R; Balakrishnan K; Kumar R; Kumar S; Amin P; Gupta PK
ACS Infect Dis; 2024 Jun; 10(6):1871-1889. PubMed ID: 38829047
[TBL] [Abstract][Full Text] [Related]
10. Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis.
Momeni A; Rasoolian M; Momeni A; Navaei A; Emami S; Shaker Z; Mohebali M; Khoshdel A
J Liposome Res; 2013 Jun; 23(2):134-44. PubMed ID: 23350940
[TBL] [Abstract][Full Text] [Related]
11. Recent advances and new strategies on leishmaniasis treatment.
Roatt BM; de Oliveira Cardoso JM; De Brito RCF; Coura-Vital W; de Oliveira Aguiar-Soares RD; Reis AB
Appl Microbiol Biotechnol; 2020 Nov; 104(21):8965-8977. PubMed ID: 32875362
[TBL] [Abstract][Full Text] [Related]
12. Innovative Solutions for the Control of Leishmaniases: Nanoscale Drug Delivery Systems.
Wagner V; Minguez-Menendez A; Pena J; Fernández-Prada C
Curr Pharm Des; 2019; 25(14):1582-1592. PubMed ID: 31223081
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Nanosystems and Strategies for Managing Leishmaniasis.
Vaghela R; Kulkarni PK; Osmani RAM; Bhosale RR; Naga Sravan Kumar Varma V
Curr Drug Targets; 2017; 18(14):1598-1621. PubMed ID: 27033193
[TBL] [Abstract][Full Text] [Related]
14. Metallic Nanoparticles: A New Frontier in the Fight Against Leishmaniasis.
Guerra RO; do Carmo Neto JR; de Albuquerque Martins T; Farnesi de-Assunção TS; Junior VR; de Oliveira CJF; Silva ACA; da Silva MV
Curr Med Chem; 2022; 29(26):4547-4573. PubMed ID: 35220932
[TBL] [Abstract][Full Text] [Related]
15. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
[TBL] [Abstract][Full Text] [Related]
16. Nanotechnological Strategies for Treatment of Leishmaniasis--A Review.
de Almeida L; Terumi Fujimura A; Del Cistia ML; Fonseca-Santos B; Braga Imamura K; Michels PAM; Chorilli M; Graminha MAS
J Biomed Nanotechnol; 2017 Feb; 13(2):117-33. PubMed ID: 29376626
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application].
Henao HH; Osorio Y; Saravia NG; Gómez A; Travi B
Biomedica; 2004 Dec; 24(4):393-402. PubMed ID: 15678803
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of amiodarone and dronedarone, as antiarrhythmic drugs, in treatment of leishmaniasis.
Oryan A; Bemani E; Bahrami S
Acta Trop; 2018 Sep; 185():34-41. PubMed ID: 29689189
[TBL] [Abstract][Full Text] [Related]
19. Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis.
Rajabi O; Layegh P; Hashemzadeh S; Khoddami M
Dermatol Ther; 2016 Sep; 29(5):358-363. PubMed ID: 27073044
[TBL] [Abstract][Full Text] [Related]
20. Liposomes versus lipid nanoparticles: comparative study of lipid-based systems as oryzalin carriers for the treatment of leishmaniasis.
Lopes RM; Gaspar MM; Pereira J; Eleutério CV; Carvalheiro M; Almeida AJ; Cruz ME
J Biomed Nanotechnol; 2014 Dec; 10(12):3647-57. PubMed ID: 26000378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
